

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT THE APPROVAL BY THE HAINAN PROVINCIAL MEDICAL PRODUCTS ADMINISTRATION FOR THE IMPORT OF MEDICAL DEVICES

This announcement is voluntarily made by China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to keep the shareholders of the Company and potential investors informed of the latest business development of the Group.

The board of directors (the “**Board**”) of the Company announces that the import of (i) the Neutron Irradiation System for Boron Neutron Capture Therapy (“**BNCT**”) (Model Number: BNCTS-2-3), and (ii) the Treatment Planning Program for Boron Neutron Capture Therapy (Model Number: BNCTDE-1) (collectively, the “**Medical Devices**”), was approved by the Hainan Provincial Medical Products Administration on 28 January 2024, as urgently needed medical devices for use by the BNCT cancer treatment centre in the Boao Lecheng International Medical Tourism Pilot Zone of Hainan Free Trade Port, the People’s Republic of China (the “**BNCT Centre**”).

As disclosed in the third quarterly report of the Company for the nine months ended 30 September 2023, Pengbo (Hainan) Medical Technology Co., Ltd.* (鵬博(海南)硼中子醫療科技有限公司) (“**Pengbo (Hainan)**”), an indirect wholly-owned subsidiary of the Company, entered into a site admission and investment agreement (the “**Site Admission Agreement**”) with the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration (the “**Administration**”) on 28 February 2022. Pursuant to the Site Admission Agreement, Pengbo (Hainan) has committed to build and to operate the BNCT Centre by adoption of the accelerator-based BNCT system covering the cyclotron accelerator, dose calculation program and related medical device for BNCT treatment to be procured and supplied by Sumitomo Heavy Industries, Ltd. (“**Sumitomo**”).

In June 2022, Pengbo (Hainan) signed a bundle of sales contract, service contract and a memorandum of understanding with Sumitomo in respect of the supply of the BNCT system together with the initial spare parts and the provision of the operation and maintenance services required for commencement of the operation of the BNCT Centre. The construction works of the BNCT Centre began in November 2022. In December 2022, the BNCT Centre was granted with the Practice License of Medical Institution* (醫療機構執業許可證) by the Administration for a term of five years until December 2027.

The construction works of the BNCT Centre had been progressing under planned schedule. Installation of the BNCT system will start once the structural construction of the facility is completed. The BNCT Centre is targeted to commence operation in late 2024 or early 2025.

ABOUT THE MEDICAL DEVICES

The Medical Devices are produced and supplied by Sumitomo and will be used in treating unresectable locally advanced or locally recurrent head and neck cancer in the BNCT Centre.

The Neutron Irradiation System for BNCT is a compact BNCT treatment system that can be installed in hospitals. It consists of a proton accelerator, a proton beam transport system(s), a neutron irradiation device(s), and other relevant devices. A proton beam from the accelerator is converged or deflected by the transport system to strike the target placed on the neutron irradiation device. The target is made of beryllium and the collision between protons and beryllium atomic nuclei induces a nuclear reaction generating neutrons having very high energy. Relevant devices in the Neutron Irradiation System for BNCT moderate and reduce neutron energy and safely produce a stable neutron beam suitable for BNCT to a patient.

The Treatment Planning Program for BNCT calculates dose distributions achieved in BNCT based on contour information (body contour, organ shape, bone region, shape/ components of treatment area, and biological parameters) and irradiation conditions (irradiation equipment, number of irradiation ports, shape of collimator, isocentre, irradiation angle, and blood drug concentration) to assist physicians in developing treatment plans with BNCT.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 30 January 2024

* *The English name the PRC entity referred to in this announcement is a translation from its Chinese name and is for identification purposes only. If there is any inconsistency, the Chinese name shall prevail.*

As at the date of this announcement, the board of Directors comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song; one non-executive Director, namely, Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.